There are currently 17 Alzheimer's treatments being tested in Phase 3 clinical trials that are on track to reach the market within five years. However, dozens of research institutions across the country are struggling to enroll eligible candidates for the trials, putting a halt to research.
The GAP Foundation commissioned a survey of 2,056 individuals age 18 and older to learn more about Americans' perception of Alzheimer's and their willingness to participate in trials.
The survey found while almost 60 percent of Americans said they are willing or would consider participating in a clinical trial for Alzheimer's disease, less than 10 percent are actually doing so.
These low rates of participation suggest that Americans want to help but don't have the tools and information needed to do so.
More articles on infection control and clinical quality:
18 overdose deaths cited in the license suspension of Seattle Pain Centers' director
Many elderly patients receive, use medications inappropriately
Providers don't understand CT scan cancer risk, study suggests